title: Status epilepticus associated with platinum chemotherapy in a patient with cervical cancer: a case report.
abstract: BACKGROUND
  While peripheral neuropathy is a common side effect of platinum-based chemotherapy, central nervous system (CNS) toxicity, such as encephalopathy or seizures, appears to be rare. This manuscript describes the only reported case of nonconvulsive status epilepticus associated with cisplatin in a cervical cancer patient who does not have other underlying medical conditions.
  
  
  METHODS
  The patient is a 54-year-old Chinese female with recurrent stage IIIB moderately differentiated squamous cell carcinoma of the cervix who was being treated with cisplatin and topotecan. During the sixth cycle of this regimen, the patient presented with mental status changes. While imaging and laboratory values were within normal limits, the patient's EEG revealed nonconvulsive status epilepticus. After appropriate intervention, she made a complete recovery with no further seizures. The patient currently remains on antiepileptic therapy, but is no longer receiving cisplatin.
  
  
  CONCLUSIONS
  Patients who present with new onset seizures should primarily be evaluated for underlying medical conditions. Among patients who are suspected to have CNS side effects associated with platinum use, we recommend avoidance of platinum agents in future chemotherapeutic regimens. Although rare, providers should be aware of the potential for CNS toxicity associated with this drug class.
authors.affiliation: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Unit 1362, 1155 Herman Pressler, CPB6.3279, Houston, TX, 77030-3721, USA. llholman@mdanderson.org.
authors.forename: Laura L
authors.initials: LL
authors.lastname: Holman
authors.affiliation: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 159 Tianzhou Road, Xuhui Area, Shanghai, 200030, China. renyulan79@126.com.
authors.forename: Yulan
authors.initials: Y
authors.lastname: Ren
authors.affiliation: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Unit 1362, 1155 Herman Pressler, CPB6.3279, Houston, TX, 77030-3721, USA. swestin@mdanderson.org.
authors.forename: Shannon N
authors.initials: SN
authors.lastname: Westin
mesh_terms: D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012640:Seizures / Q000139:chemically induced / Q000473:pathology; D013226:Status Epilepticus / Q000139:chemically induced / Q000473:pathology*; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects*; D002583:Uterine Cervical Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
chemical_list: D019772:Topotecan; D017239:Paclitaxel; D002945:Cisplatin